Zhao Guo-Zhen, Lu Hai-Tian, Yan Shi-Yan, Guo Yu-Hong, Ye Hao-Ran, Jiang Li, Zhang Yao-Fu, Hu Jing, Guo Shi-Qi, DU Yuan, Liu Fang-Yu, Li Bo, Liu Qing-Quan
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Chinese Medicine,Beijing Evidence-based Chinese Medicine Center Beijing 100010, China Beijing University of Chinese Medicine Beijing 100029, China.
Beijing University of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2023 Feb;48(4):1132-1136. doi: 10.19540/j.cnki.cjcmm.20221027.501.
In observational studies, herbal prescriptions are usually studied in the form of "similar prescriptions". At present, the classification of prescriptions is mainly based on clinical experience judgment, but there are some problems in manual judgment, such as lack of unified criteria, labor consumption, and difficulty in verification. In the construction of a database of integrated traditional Chinese and western medicine for the treatment of coronavirus disease 2019(COVID-19), our research group tried to classify real-world herbal prescriptions using a similarity matching algorithm. The main steps include 78 target prescriptions are determined in advance; four levels of importance labeling shall be carried out for the drugs of each target prescription; the combination, format conversion, and standardization of drug names of the prescriptions to be identified in the herbal medicine database; calculate the similarity between the prescriptions to be identified and each target prescription one by one; prescription discrimination is performed based on the preset criteria; remove the name of the prescriptions with "large prescriptions cover the small". Through the similarity matching algorithm, 87.49% of the real prescriptions in the herbal medicine database of this study can be identified, which preliminarily proves that this method can complete the classification of herbal prescriptions. However, this method does not consider the influence of herbal dosage on the results, and there is no recognized standard for the weight of drug importance and criteria, so there are some limitations, which need to be further explored and improved in future research.
在观察性研究中,中药方剂通常以“类方”的形式进行研究。目前,方剂分类主要基于临床经验判断,但人工判断存在一些问题,如缺乏统一标准、耗费人力、难以验证等。在构建2019冠状病毒病(COVID-19)中西医结合治疗数据库时,我们的研究团队尝试使用相似性匹配算法对真实世界的中药方剂进行分类。主要步骤包括:预先确定78首目标方剂;对每首目标方剂的药物进行四级重要性标注;对中药数据库中待识别方剂的药物进行组合、格式转换和名称规范;逐一计算待识别方剂与各目标方剂之间的相似度;根据预设标准进行方剂判别;去除“大复方覆盖小复方”的方剂名称。通过相似性匹配算法,本研究中药数据库中87.49%的真实方剂能够被识别,初步证明该方法能够完成中药方剂的分类。然而,该方法未考虑中药剂量对方剂分类结果的影响,且药物重要性权重及标准尚无公认标准,因此存在一定局限性,有待在今后研究中进一步探索和完善。